Detailed Phase III results of AstraZeneca PLC and Merck & Co. Inc.'s PARP inhibitor Lynparza (olaparib) impressed at the European Society for Medical Oncology meeting on 30 September. The results showed Lynparza doubled the time to radiographic progression-free survival (rPFS) in men with BRCA1/2 or ATM-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed on hormone therapy.
They also showed an improvement in a broader population of men with homologous recombination repair (HRRm) gene mutations, though the...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

